Amarin (AMRN) to Release Earnings on Wednesday

Amarin (NASDAQ:AMRN) is set to release its earnings data before the market opens on Wednesday, May 1st. Analysts expect Amarin to post earnings of ($0.04) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Amarin (NASDAQ:AMRN) last issued its quarterly earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.04. The company had revenue of $74.71 million during the quarter, compared to the consensus estimate of $72.46 million. Amarin had a negative net margin of 19.26% and a negative return on equity of 10.47%. On average, analysts expect Amarin to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Amarin Trading Up 2.0 %

NASDAQ AMRN opened at $0.88 on Wednesday. The firm has a market capitalization of $362.74 million, a price-to-earnings ratio of -6.31 and a beta of 1.98. Amarin has a 1 year low of $0.65 and a 1 year high of $1.49. The firm’s 50 day simple moving average is $0.99 and its 200 day simple moving average is $0.93.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Amarin in a research note on Friday, January 12th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $1.08.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.